Skip to main content

Zaccardelli David's Form 4 filing

Verona Pharma plc (VRNA) · filed Oct 22, 2024

Accession no.
0001104659-24-110659
Filed
Oct 22, 2024
Trade date
Oct 18-22, 2024
Filing delay
4 days
Rule 10b5-1 plan
Checked

This filing lists 3 non-derivative transactions. Open-market sales total $2.25M. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Zaccardelli DavidCIK 0001627642Director, Officer (President and CEO)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Oct 18, 2024Ordinary SharesSSaleDisposed−245,784$4.38F3−$1,076,533.9215,004,920Direct
Oct 21, 2024Ordinary SharesSSaleDisposed−110,456$4.38F4−$483,797.2814,894,464Direct
Oct 22, 2024Ordinary SharesSSaleDisposed−157,912$4.39F5−$693,233.6814,736,552Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F3

The price reported represents a weighted average price of the ADSs divided by eight (8). The securities were sold in multiple transactions at prices ranging from $4.3750 to $4.4063 per Ordinary Share, inclusive (or $35.00 to $35.25 per ADS, inclusive). The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F4

The price reported represents a weighted average price of the ADSs divided by eight (8). The securities were sold in multiple transactions at prices ranging from $4.3750 to $4.3913 per Ordinary Share, inclusive (or $35.00 to $35.13 per ADS, inclusive). The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F5

The price reported represents a weighted average price of the ADSs divided by eight (8). The securities were sold in multiple transactions at prices ranging from $4.375 to $4.4438 per Ordinary Share, inclusive (or $35.00 to $35.55 per ADS, inclusive). The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)